Multi-Faceted role of naturally occurring autoantibodies in fighting pathogens

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 100-113

  Bouhlal, Hicham ^a,b   Kaveri, Srini ^c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD209 ANTIGEN; CHEMOKINE RECEPTOR CCR5; COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METRONIDAZOLE; PALIVIZUMAB; PLACEBO; PROBIOTIC AGENT; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIFAMPICIN; VANCOMYCIN; VIRUS RECEPTOR; ZIDOVUDINE; AUTOANTIGEN; IMMUNOGLOBULIN M;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL IMMUNITY; CLOSTRIDIUM DIFFICILE INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; GRAFT REJECTION; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MEASLES; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; THROMBOCYTOPENIA; VIRUS IMMUNITY; VIRUS TRANSMISSION; BACTERIAL INFECTION; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; REVIEW; VIROLOGY; VIRUS INFECTION;

AUTOANTIBODIES; AUTOANTIGENS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; RECEPTORS, VIRUS; VIRUS DISEASES;

EID: 84866782743     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_8     Document Type: Article

References (96)

1. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995; 7:812-8. doi:10.1016/0952-7915(95)80053-0 PMID:8679125 (Pubitemid 26038522)
2. Hayakawa K, Asano M, Shinton SA et al. Positive selection of natural autoreactive B cells. Science 1999; 285:113-6. doi:10.1126/science.285.5424.113 PMID:10390361 (Pubitemid 29307578)
3. Ochsenbein AF, Fehr T, Lutz C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286:2156-9. doi:10.1126/science.286.5447.2156 PMID:10591647 (Pubitemid 129516290)
4. Bartlett JG, Perl TM. The new Clostridium difficile-what does it mean? N Engl J Med 2005; 353:2503-5. doi:10.1056/NEJMe058221 PMID:16322604 (Pubitemid 41770171)
5. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother 2004; 53:882-4. doi:10.1093/jac/dkh176 PMID:15073160 (Pubitemid 38660298)
6. McPherson S, Rees CJ, Ellis R et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49:640-5. doi:10.1007/s10350-006-0511-8 PMID:16525744 (Pubitemid 43723812)
7. Hassett J, Meyers S, McFarland L et al. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 1995; 20:S266-8. doi:10.1093/clinids/20.Supplement-2.S266 PMID:7548571
8. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:S32-42. doi:10.1086/521860 PMID:18177219 (Pubitemid 351323663)
9. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization; 1997.
10. Halstead SB. Dengue. Lancet 2007; 370:1644-52. doi:10.1016/S0140-6736(07) 61687-0 PMID:17993365 (Pubitemid 350052290)
11. Schexneider KI, Reedy EA. Thrombocytopenia in dengue fever. Curr Hematol Rep 2005; 4:145-8. PMID:15720964
12. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304:1135-47. doi:10.1056/ NEJM198105073041904 PMID:7012619 (Pubitemid 11099209)
13. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008. doi:10.1056/NEJMra010501 PMID:11919310 (Pubitemid 34983251)
14. Oishi K, Inoue S, Cinco MT et al. Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. J Med Virol 2003; 71:259-64. doi:10.1002/jmv.10478 PMID:12938201 (Pubitemid 37048469)
15. Saito M, Oishi K, Inoue S et al. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol 2004; 138:299-303. doi:10.1111/j.1365-2249.2004.02626.x PMID:15498040 (Pubitemid 39472447)
16. Honda S, Saito M, Dimaano EM et al. Increased Phagocytosis of Platelets from Patients with Secondary Dengue Virus Infection by Human Macrophages. Am J Trop Med Hyg 2009; 80:841-5. PMID:19407135
17. Ascher DP, Laws HF, Haves CG. The use of intravenous gammaglobulin in dengue fever, a case report. Southeast Asian J Trop Med Public Health 1989; 20:549-54. PMID:2484144 (Pubitemid 20237362)
18. Ostronoff M, Ostronoff F, Florencio R et al. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin. Clin Infect Dis 2003; 36:1623-4. doi:10.1086/374870 PMID:12802766 (Pubitemid 36783350)
19. Dimaano EM, Saito M, Honda S et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007; 77:1135-8. PMID:18165536 (Pubitemid 351837807)
20. Lin CF, Lei HY, Liu CC et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001; 63:143-9. doi:10.1002/1096-9071(20000201)63:2<143::AID-JMV1009>3.0.CO;2-L PMID:11170051 (Pubitemid 32142271)
21. Sibéril S, Elluru SR, Negi VS et al. Intravenous immunoglobulin in autoimmune andinflammatory diseases: More than mere transfer of antibodies. Transfus Apheresis Sci 2007; 37:103-7 doi:10.1016/j. transci.2007.01.012.
22. Andersson U, Bjork L, Skansen-Saphir U et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-42. doi:10.1111/j.1600-065X.1994.tb00855.x PMID:7927412 (Pubitemid 24232670)
23. Cines DB, Bussel JB, Liebman HA et al. The ITP syndrome: Pathogenic and clinical diversity. Blood 2009; 113:6511-21. doi:10.1182/blood-2009-01-129155 PMID:19395674
24. Avirutnan P, Punyanadee N, Noisaran S et al. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193:1078-88. doi:10.1086/500949 PMID:16544248
25. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007; 30:329-40. doi:10.1016/j.cimid.2007.05.010 PMID:17645944 (Pubitemid 47450087)
26. Malasit P. Complement and dengue hemorrhagic fever/dengue shock syndrome. Southeast Asian J Trop Med Public Health 1987; 18:316-20. PMID:3501613
27. Morrison TE, Heise MT. The host complement system and arbovirus pathogenesis. Curr Drug Targets 2008; 9:165-72. doi:10.2174/138945008783502485 PMID:18288968 (Pubitemid 351461014)
28. Bokisch VA, Muller-Eberhard HJ, Dixon FJ. The role of complement in hemorrhagic shock syndrome (dengue). Trans Assoc Am Physicians 1973; 86:102-10. PMID:4132983
29. Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193:1078-88. doi:10.1086/500949 PMID:16544248
30. Avirutnan P, Fuchs A, Hauhart RE et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010; 207:793-806. doi:10.1084/jem.20092545 PMID:20308361
31. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36. doi:10.1097/01.qco. 0000244047.31135.fa PMID:16940865 (Pubitemid 44338101)
32. Lin CF, Lei HY, Shiau AL et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003; 69:82-90. doi:10.1002/jmv.10261 PMID:12436482 (Pubitemid 35403658)
33. Morris SK, Dzolganovski B, Beyene J et al. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009; 9:106-14. doi:10.1186/1471-2334-9-106 PMID:19575815
34. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes 2004; 11:77-86. PMID:15960905 (Pubitemid 40064892)
35. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60-5. PMID:14759337 (Pubitemid 38076249)
36. Bowman JS, Green M, Scnatlebury V et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991; 5:294-300. PMID:21170278
37. Gane E, Saliba F, Valdecasea G et al. Randomised trial of efficiacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997; 350:1729-33. doi:10.1016/ S0140-6736(97)05535-9 PMID:9413463
38. Campbell AL, Herold BC. Strategies for the prevention of cytomegalovirus infection and disease in pediatric liver transplantation recipients. Pediatr Transplant 2004; 8:619-27. doi:10.1111/j.1399-3046.2004.00242.x PMID:15598337 (Pubitemid 40052366)
39. Snydman DR, McIver J, Leszczynski J et al. A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 1984; 38:553-7. doi:10.1097/00007890-198411000-00026 PMID:6093299 (Pubitemid 15207420)
40. Green M. Viral infections and pediatric liver transplantation. Pediatr Transplant 2002; 6:20-4. doi:10.1034/ j.1399-3046.2002.1p048.x PMID:11906638
41. Snydman DR, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119:984-91. PMID:8214995 (Pubitemid 23334654)
42. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIG). Ther Immunol 1994; 1:269-77. PMID:7584501 (Pubitemid 24344443)
43. Kazatchkine MD, Kaveri SV. Immunomodulation of auto- immune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55. doi:10.1056/NEJMra993360 PMID:11547745
44. Bouhlal H, Hocini H, Quillent-Gregoire C et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166:7606-11. PMID:11390517 (Pubitemid 32525642)
45. Requena M, Bouhlal H, Nasreddine N et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008; 123:508-18. doi:10.1111/j.1365- 2567.2007.02717.x PMID:17999675 (Pubitemid 351280964)
46. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9:551-62. doi:10.1016/S0952-7915(97)80110-0 PMID:9287172 (Pubitemid 27390052)
47. Deng, H., Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6. doi:10.1038/381661a0 PMID:8649511 (Pubitemid 26197679)
48. van't Wout AB, Kootstra NA, Mulder-Kampinga GA et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060-7. doi:10.1172/JCI117560 PMID:7962552 (Pubitemid 24348247)
49. Connor RI, Sheridan KE, Ceradini D et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8. doi:10.1084/jem.185.4.621 PMID:9034141 (Pubitemid 27098147)
50. Rana S, Besson G, Cook DG et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates re- sulting from the ccr5 mutation. J Virol 1997; 71:3219-27. PMID:9060685 (Pubitemid 27119969)
51. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5. doi:10.1038/382722a0 PMID:8751444 (Pubitemid 26282179)
52. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77. doi:10.1016/ S0092-8674(00)80110-5 PMID:8756719 (Pubitemid 26272077)
53. Cairns JS, D'Souza MP. Chemokines and HIV-1 second receptors: The therapeutic connection. Nat Med 1998; 4:563-8. doi:10.1038/nm0598-563 PMID:9585229 (Pubitemid 28237354)
54. Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731-41. doi:10.1097/00002030- 200209060-00004 PMID:12218383
55. Lopalco L, Pastori C, Cosma A et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109-15. doi:10.1089/088922200309458 PMID:10659050 (Pubitemid 30060981)
56. Lopalco L, Magnani Z, Confetti C et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: A follow-up study. AIDS Res Hum Retroviruses 1999; 15:1079-85. doi:10.1089/088922299310377 PMID:10461828 (Pubitemid 29379803)
57. Ditzel HJ, Rosenkilde MM, Garred P et al. The CCR5 receptor acts as an alloantigen in CCR532 homozygous individuals: Identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci USA 1998; 95:5241-5. doi:10.1073/pnas.95.9.5241 PMID:9560260 (Pubitemid 28208582)
58. Barassi C, Soprana E, Pastori C et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 2005; 79:6848-58. doi:10.1128/JVI.79.11.6848-6858.2005 PMID:15890924 (Pubitemid 40677317)
59. Royce RA, Sena A, Cates W et al. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-8. doi:10.1056/ NEJM199704103361507 PMID:9091805 (Pubitemid 27163861)
60. Reece JC, Handley AJ, Anstee EJ et al. HIV-1 selection by epidermal dendritic cells during trans- mission across human skin. J Exp Med 1998; 187:1623-31. doi:10.1084/jem.187.10.1623 PMID:9584140 (Pubitemid 28235103)
61. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9. doi:10.1056/NEJM199807023390107 PMID:9647878
62. Hirsch VM, Sharkey ME, Brown CR et al. Vpx is required for dissemination and pathogenesis of SIV(SM PBj: Evidence of macrophage-dependent viral amplification. Nat Med 1998; 4:1401-8. doi:10.1038/3992 PMID:9846578 (Pubitemid 28553463)
63. Zhang Z, Schuler T, Zupancic M et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286:1353-7. doi:10.1126/science.286.5443.1353 PMID:10558989 (Pubitemid 29535894)
64. Olson WC, Rabut GE, Nagashima KA et al. Differential inhibition of human immunodeficiency virus type fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73:4145-55. PMID:10196311 (Pubitemid 29189860)
65. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIG). Ther Immunol 1994; 1:269-77. PMID:7584501 (Pubitemid 24344443)
66. Piguet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 2002; 119:365-9. doi:10.1046/j.1523-1747.2002.01840.x PMID:12190858 (Pubitemid 35001945)
67. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004; 20:247-53. doi:10.1016/S1074-7613(04)00053-6 PMID:15030769 (Pubitemid 38388227)
68. Turville SG, Arthos J, Donald KM et al. HIV gp120 receptors on human dendritic cells. Blood 2001; 98:2482-8. doi:10.1182/blood.V98.8.2482 PMID:11588046
69. Moris A, Nobile C, Buseyne F et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004; 103:2648-54. doi:10.1182/blood-2003-07-2532 PMID:14576049 (Pubitemid 38393020)
70. Buseyne F, Le Gall S, Boccaccio C et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001; 7:344-9. doi:10.1038/85493 PMID:11231634 (Pubitemid 32224351)
71. Geijtenbeek TB, Engering A, Van Kooyk Y. DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J Leukoc Biol 2002; 71:921-31. PMID:12050176
72. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587-97. doi:10.1016/S0092-8674(00)80694-7 PMID:10721995
73. Jameson B, Baribaud F, Pohlmann S et al. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002; 76:1866-75. doi:10.1128/JVI.76.4.1866-1875.2002 PMID:11799181 (Pubitemid 34094633)
74. Geijtenbeek TB, Torensma R, van Vliet SJ et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100:575-85. doi:10.1016/ S0092-8674(00)80693-5 PMID:10721994
75. Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ et al. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem 277:11314-20. doi:10.1074/jbc.M111532200 PMID:11799126
76. Dalgleish AG. The immune response to HIV: Potential for immunotherapy? Immunol Today 1995; 16:356-8. doi:10.1016/0167-5699(95)80156-1 PMID:7576075
77. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991; 5:1405-17. doi:10.1097/ 00002030-199112000-00001 PMID:1814326
78. Aukrust P, Liabakk NB, Muller F et al. Serum levels of tumor necrosis factor-a (TNF-a) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlation to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169:420-4. doi:10.1093/infdis/169.2.420 PMID:7906293 (Pubitemid 24045606)
79. Godfried MH, van der Poll T, Weverling GJ et al. Soluble receptors for tumor necrosis factor as predictor of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 169:739-45. doi:10.1093/infdis/169.4.739 PMID:7907641
80. Aukrust P, Frøland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43. PMID:7919327 (Pubitemid 24296369)
81. Achiron A, Margalit R, Hershkoviz R et al. Intravenous immunoglobulin treatment of experimental T-cell- mediated autoimmune disease. J Clin Invest 1994; 93:600-5. doi:10.1172/JCI117012 PMID:8113397
82. Aukrust P, Frøland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-43. PMID:7919327
83. Olsson I, Lantz M, Nilsson E et al. Isolation and characterization of a tumor necrosis factor binding protein from human urine. Eur J Haematol 1989; 42:270-5. doi:10.1111/j.1600-0609.1989.tb00111.x PMID:2924890 (Pubitemid 19086211)
84. Van Zee KJ, Kohno T, Fischer E et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and protect against excessive tumor necrosis factor-a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-9. PMID:1317575
85. Vandenabeele P, Declercq W, Beyaert R et al. Two tumor necrosis factor receptors: Structure and function. Trends Cell Biol 1995; 5:392-9. doi:10.1016/S0962-8924(00)89088-1 PMID:14732063
86. Mofenson LM, Bethel J, Moye J et al. Effect of intravenous immunoglobulin (IVIG) on CD4/ lymphocyte decline in HIV infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993; 6:1103-13. PMID:8105072 (Pubitemid 23293243)
87. Palella FJJ, Delaney KM, Moorman AC et al. Declining mor- bidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-60. doi:10.1056/NEJM199803263381301 PMID:9516219
88. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362:22-9. doi:10.1016/S0140-6736(03)13802-0 PMID:12853195 (Pubitemid 36835816)
89. Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998; 12:F71-7. doi:10.1097/00002030-199808000- 00003 PMID:9631134 (Pubitemid 28241394)
90. Kaplan G, Thomas S, Fierer DS et al. Thalidomide for the treat- ment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16:1345-55. doi:10.1089/08892220050140892 PMID:11018854
91. Rizzardi GP, Vaccarezza M, Capiluppi B et al. Cyclosporin A in combination with HAART in primary HIV-1 infection. J Biol Regul Homeost Agents 2000; 14:79-81. PMID:10763900 (Pubitemid 32288573)
92. Vermeulen JN, Prins JM, Bunnik E et al. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses 2007; 23:1348-53. doi:10.1089/aid.2006.0210 PMID:18184076
93. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 1994; 97(suppl 1):59-67. PMID:8033437 (Pubitemid 24235269)
94. Mofenson LM, Moye J Jr., Bethel J et al. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4 counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. JAMA 1992; 268:483-8. doi:10.1001/jama.268.4.483 PMID:1352363
95. Spector SA, Gelber RD, McGrath N et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994; 331:1181-7. doi:10.1056/ NEJM199411033311802 PMID:7935655 (Pubitemid 24331335)
96. Kiehl MG, Stoll R, Broder M et al. controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection. Arch Intern Med 1996; 156:2545-50. doi:10.1001/archinte.156.22.2545 PMID:8951297 (Pubitemid 26404791)